Introduction: Schizophrenia is a chronic mental illness that negatively affects the quality of life of the patient and his family. Primary therapy in the treatment of schizophrenia is antipsychotics.
Introduction
Schizophrenia is a chronic mental illness with a prevalence of about one percent. years, while in females between 25 and 34 years. 4, 5 For the development of schizophrenia, biological factors, social factors and factors of individual life experience are of great importance. 6, 7 The primary symptoms of schizophrenia fall into disorders of the association of thought, affect disorder, ambivalence and autism (four A syndrome, by Bleuler) . 8, 9 Schizophrenia is characterized by an altered opinion in form and content. [10] [11] [12] [13] [14] [15] Primary therapy in the treatment of schizophrenia represents pharmacotherapy, with antipsychotics playing a significant role. 16, 17 The World Health Organization (WHO) , under the quality of life, implies the perception of individuals on their position in life, in the context of the culture and value systems in which they live and in relation to their goals, expectations, standards and concerns about their environment. [18] [19] [20] Research on the quality of life of mentally ill people appeared at the beginning of the nineties, followed by a plethora of studies on quality of life of patients with somatic symptoms. [21] [22] [23] There is no doubt that the assessment of the quality of life of psychiatric patients is in relation to the objective social factors, physical health, emotional, family and cultural factors. 24, 25 Aim of the study
The aim of this study is to compare the quality of life of schizophrenic patients treated with depot neuroleptics and without depot neuroleptics.
Patients and Methods
The study included patients treated in the period from December, 2011 to September, 2012, at the Center for Men tal Health, PHI "Health Center" Gradiska. The investigation was conducted in compliance with the De cla ration of Helsinki on medical research and the principles of good scientific practice. Initially, 67 patients were selected for the study, but only 64 were further included in the study, aged 18-60 years, out of which 36 were female subjects (56.3%) and 28 male (43.7%). Patients whose intellectual abilities were at the level of light mental retardation were excluded from the study.
Experimental group consisted of patients suffering from schizophrenia, treated with depot neuroleptics and with or without additional oral therapy (n = 32). The control group consisted of patients suffering from schizophrenia and receiving oral therapy exclusively (n = 32). Informed consent was obtained from all study subjects. Based on medical history, socio-demographic data, and medical records assessment, we obtained data on the age, marital and employment status, level of education and the presence of somatic diseases in patients. Determination of body weight was done using calibrated scales and recorded values were expressed in kg; body height was determined using stadiometer and recorded values were expressed in cm. Quality of Life Questionnaire and BPRS were filled by the examiners after examinees provided their answers to the questions.
Statistical analysis was performed using SPSS (Statistical Package for the Social Sciences), version 20, as the analytical statistical tool.
Data were analyzed using descriptive statistics. c 2 -test of independence was used to determine the relationship between two categorical variables.
Results
The results of data analysis showed that the average age of the examinees was 44.19 ± 7.785 (experimental group: 43.31 ± 6.879 and control: 45.06 ± 8.617 years). Age of the examinees in both groups is shown in Table 1 . N= number of subjects Min= age of the youngest subject Max= age of the oldest subject Range=, average age of the subject Median= mediana, Mean= arithmetic mean Std. Dev.= Standard deviation CV (%) = coefficient of variation.
Using a Man-Whitney U test of rank to analyze the data on arterial pressure, no significant difference was found in systolic arterial pressure values between the experimental (Md = 122.50, n = 32) and control (Md = 122.50, n = 32) group, U = 440 000, z = -0977, p = 0328, r = 0.12, as well as in diastolic arterial pressure between the experimental (Md = 82.50, n = 32) and control (Md = 87.50, n = 32) group, U = 487 000, z = -0341, p = 0.733, r = 0.04.
Results showing the level of satisfaction in quality of life: housing, friends, visits to cultural events and religiosity are presented in Table 2 .
Using the Chi-square test of independence for analysis, data showed that there were no statistically significant differences in both groups compared to inflammatory therapy (c2 = 1570, SS = 2, p = 0.456), as well as the presence of frequent mood changes (c 2 = 0077, SS = 1, p = 0.781); while the examination of hallucinations showed statistically significant difference between two groups (c 2 = 8.400, df = 3, p = 0.038). Neuroleptics in relation to the number of patients are presented in Table 3 . The presence of disorientation was not found in the study groups.
Discussion
Measures of the quality of life of schizophrenic patients are used for different purposes. In the first place it serves the purpose to assess the performance of methods of treatment, so called application of new medications, including the widely conceived programs for the prevention of mental disorders. [21] [22] [23] [24] [25] [26] [27] Research studies of Salokangas et al. showed that the quality of life of schizophrenic patients in Finland was higher in those subjects who lived in good marital or partnership relationships. 28, 29 The quality of life of schizophrenic patients was also examined by Holzinger et al., with participation of 605 psychiatrists in Germany, where it was shown that the highest ranked aspect of quality of life was the patient's satisfaction, i.e. social interaction, contacts and the acceptance by the people in their immediate family environment, followed by lack of symptoms and the ability to work. 30 However, the study including schizophrenic patients in Nigeria showed that their quality of life was more dependent on marital status and employment, meaning that married and employed were more satisfied with the quality of life. 31, 32 Similarly, the studies on schizophrenic patients from different cultural backgrounds, such as China, showed higher scores of quality of life achieved by employed persons living in families who were religious, and older examinees with higher incomes, but the differences were not significant. [33] [34] In contrast, our research did not show significant disparities in the quality of life of schizophrenic patients, in accordance with research conducted by Kuga A. et al. in Japan, who showed that none of the socio-demographic or objective variables affected the assessment of the quality of life of schizophrenic patients. 35 Regarding the treatment of schizophrenic patients, halo pe ridol decanoate may have a significant effect on improvement of the symptoms and behaviors in comparison to placebo, but the data to confirm this theory are extremely rare. [36] [37] [38] [39] [40] There are no visible differences between haloperidol administered in depot form or orally. For those who need this medicine and who wish to use it, the method on which the medicine enters the body is a matter of personal choice and clinical assessment. [41] [42] [43] [44] [45] Since there are clear differences between haloperidol decanoate [50] [51] [52] [53] [54] The research showed that there was small advantage of depot-forms compared to the same medicine taken orally, in terms of compatibility. However, this is not broadly applicable in everyday clinical practice. 55 Following two groups of schizophrenic patients after discharge from a psychiatric hospital during period of one year , where one group was administered oral therapy and the other a depot formulation, it was found that patients on oral therapy had higher rates of re-hospitalization and their quality of life was not better than in patients on depot medication. 56 These findings were partially in agreement with our study results that showed no difference in the quality of life of schizophrenic patients on depot preparation and those taking oral agents.
Conclusion
On the basis of the conducted research we can conclude that the results of our study are in agreement with the results of other studies. The quality of life of schizophrenic patients treated with or without depot preparations was mainly the same, with small deviations. There were no statistically significant differences between two groups based on gender, age structure, education, employment, body weight, and body height. A statistically significant difference was determined in the presence of hallucinations, which were more frequent in patients treated with depot preparations neuroleptics, in comparison to subjects without depot in therapy. Disorientation was not present in either group of examinees. These results may contribute to the treatment and improvement of quality of life of the patients suffering from this disease.
